SCHEMBL3022924

SCHEMBL3022924

CC/C(C)=C/C/C=C(\C)CC#N

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13210189 1.00 MCL1 (0.31) MCL1
SCHEMBL3022928 1.00 MCL1 (0.31) MCL1
SCHEMBL13210191 1.00 MCL1 (0.31) MCL1
SCHEMBL13210190 1.00 MCL1 (0.31) MCL1
SCHEMBL3077147 0.84 KMT2A (0.31) MCL1
SCHEMBL16516011 0.84 KMT2A (0.31) MCL1
SCHEMBL3077150 0.84 KMT2A (0.31) MCL1
SCHEMBL3642589 0.80 ALDH1A1 (0.33)
SCHEMBL15201235 0.80 ALDH1A1 (0.33)
SCHEMBL60485 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2814809-B1 NOVEL PROCESS FOR THE MANUFACTURE OF METHYL LIMONITRILE DSM IP ASSETS BV (NL) 2017-03-22 EP claimed
EP-2628723-B1 Novel process for the manufacture of methyl limonitrile DSM IP ASSETS BV (NL) 2014-09-10 EP claimed
EP-2173704-B1 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2013-09-11 EP claimed
US-20100204083-A1 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2010-08-12 US claimed
EP-2173704-A2 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2010-04-14 EP claimed
WO-2009052643-A1 ANTI-MALODOUR COMPOSITIONS GIVAUDAN SA (CH) 2009-04-30 WO claimed
WO-2009013199-A2 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2009-01-29 WO claimed
EP-3036216-B1 PROCESS FOR THE MANUFACTURE OF HYDROGENATED NITRILES DSM IP ASSETS BV (NL) 2019-06-12 EP disclosed
EP-2814809-B1 NOVEL PROCESS FOR THE MANUFACTURE OF METHYL LIMONITRILE DSM IP ASSETS BV (NL) 2017-03-22 EP disclosed
EP-2814809-B1 NOVEL PROCESS FOR THE MANUFACTURE OF METHYL LIMONITRILE DSM IP ASSETS BV (NL) 2017-03-22 EP disclosed
US-9458096-B2 Process for the manufacture of methyl limonitrile DSM IP ASSETS B.V. (NL) 2016-10-04 US disclosed
US-9458096-B2 Process for the manufacture of methyl limonitrile DSM IP ASSETS B.V. (NL) 2016-10-04 US disclosed
US-9340750-B2 Process for the manufacture of methyl limonitrile DSM IP ASSETS B.V. (NL) 2016-05-17 US disclosed
EP-2173704-A2 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2010-04-14 EP disclosed
EP-2173704-A2 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2010-04-14 EP disclosed
WO-2009052643-A1 ANTI-MALODOUR COMPOSITIONS GIVAUDAN SA (CH) 2009-04-30 WO disclosed
WO-2009013199-A3 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2009-04-02 WO disclosed
WO-2009013199-A2 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2009-01-29 WO disclosed
WO-2009013199-A2 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2009-01-29 WO disclosed
WO-2009013199-A2 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE BASF SE (DE) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204083-A1 PROCESS FOR THE PREPARATION OF ETHYLGERANONITRILE CYP51A1, ESD, CYP3A4 MCL1 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.